12th Portuguese Congress of Hypertension and Global Cardiovascular Risk
On February 22, the 12th Portuguese Congress of Hypertension and Global Cardiovascular Risk will begin with an opening ceremony at 17:30 at Tivoli Marina Vilamoura. The event, of international dimension and recognized merit, is organized by the Portuguese Society of Hypertension (SPH).
Dr. Vítor Paixão Dias, president of the Organizing Committee of the event and current director of the Internal Medicine Service of the Hospital Center of Vila Nova de Gaia / Espinho, said that "it has sought to elaborate a comprehensive program that meets the expectations of all congressmen, highlighting the round tables dedicated to the global vascular risk in the various aspects and what it implies in the daily practice of the General and Family Medicine clinic. Diabetes, dyslipidemia and vascular dementia are some of the topics discussed at the round tables. "Dr. Manuel Carvalho Rodrigues, President of SPH, explains that" hypertensive patients are often not only hypertensive and today, when we talk about treatment, we have the possibility of using a polypill that treats several risk factors, also useful in combating the lack of therapeutic adherence.
"Are coffee and chocolate good for the heart and for the soul? What about CV risk? "Is the theme chosen for the conference's inaugural conference, which will be led by Csaba Farsang of the Hungarian Hypertension Society.
The magna session "Clinical cases of the day-to-day of General and Family Medicine" will be, according to the Organizing Committee, one of the highlights of the 12th Congress of Hypertension and Global Cardiovascular Risk. "The vast majority of hypertensive patients are in primary health care and we must surely discuss, in addition to clinical cases of greater complexity, ways to improve the integration of care," says Dr. Vítor Paixão Dias.
"The state of the art in 2018" is the usual joint session between SPH and the European Society of Hypertension, where several internationally renowned individuals discuss the latest developments in the treatment of hypertension. This year, the topics under discussion are "The Kidney in Hypertension," "New Evidence in the Treatment of Hypertension Leads to New Recommendations in 2018," and "Brain and HTA: Victim or Guilty."
The usual joint sessions between SPH and societies from other countries are also part of the Congress Scientific Program, namely the Luso-Hungarian Symposium and the Luso-Brazilian Symposium.
Following the success of previous editions and in response to multiple requests and suggestions, the Organizing Committee of the 12th Portuguese Congress on Hypertension and Global Cardiovascular Risk will again include in the Scientific Program of the Congress a Postgraduate Course in Hypertension and Global Cardiovascular Risk with an essentially practical and very interactive approach. It will consist of four sessions integrated in the program, lasting 60 minutes each day of the event, taught by preachers of recognized scientific merit. The themes of the sessions are: Secondary AHT: A review for a practical approach, Treatment of AHT: What's new, HTA Resistant: What's new, MAPA, AMPA and PAA: Differences and complementarities.
Also worth mentioning is the course "Future Perspectives in the RCVG", preferably addressed to Complementary Interns of the different specialties. The course will have two sessions lasting 60 minutes each, the main themes being "Therapeutic adherence and medical inertia: new targets for treatment in the RCVG" and "New antidiabetic and CV protection".
The closing of the congress is scheduled for the 25th with the presentation "Early Vascular Aging: From EVA to SUPERNOVA", directed by Stéphane Laurent of the French Society of Hypertension.
The President of SPH adds that "it is particularly gratifying to be able to emphasize that this is a program that goes beyond the European space and extends, in a very particular way, throughout the Portuguese-speaking world." The president of the SPH also emphasizes "the scientific approval that the Congress deserved by the European Society of Hypertension, as well as the accreditation by the European Board Acreditation in Cardiology (EBAC)".